Related Experiment Video
Updated: Aug 8, 2025
09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
702
Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
Seungyong Shin1, Pyunghwajun Lee2, Jieun Han1,3
1Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea.
Tissue Engineering and Regenerative Medicine
|March 3, 2023
Summary
Nanotechnology offers a novel approach to adoptive cell therapy, enhancing chimeric antigen receptor (CAR)-engineered immune cells for cancer treatment. This nanoparticle-based strategy aims to overcome limitations of traditional CAR-T cell therapy, particularly for solid tumors.
Area of Science:
- Immunotherapy
- Nanotechnology
- Cellular Engineering
Background:
- Chimeric antigen receptor (CAR)-engineered T cell (CAR-T) therapy shows promise for hematological cancers.
- CAR-T therapy faces challenges including limited efficacy in solid tumors, complex procedures, and high manufacturing costs.
Purpose of the Study:
- To introduce nanoparticle-based advanced CAR immune cell therapy.
- To explore future perspectives on immune cell reprogramming using nanotechnology.
Main Methods:
- Utilizing nanoparticles as a delivery platform for CAR engineering.
- Applying nanotechnology to enhance CAR-T, CAR-natural killer, and CAR-macrophage therapies.
Main Results:
- Nanoparticles offer unique physicochemical properties for targeted delivery and drug delivery.
- Nanoparticle-based CAR therapy can be extended to natural killer and macrophage cells, addressing limitations of traditional CAR-T cells.
Conclusions:
- Nanotechnology presents a promising alternative to conventional CAR-T cell therapy.
- Nanoparticle-mediated immune cell reprogramming holds potential for improved cancer immunotherapy.
